July 12th, 2024
12:00 PM Pacific
Register now for a special presentation on new DYNE-101 ACHIEVE Clinical Trial Data by Chief Medical Affairs Officer, Ash Dugar, PhD, MBA. Click here to download Dyne's recent letter to the DM1 Community.
Biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions. Click here to learn more about Dyne.
Click here to find all our upcoming Meet the DM Drug Developers dates!
Presenters to Include

Ash Dugar, PhD, MBA
Chief Medical Affairs Officer
Dr. Dugar is the chief medical affairs officer at Dyne Therapeutics. He brings to Dyne over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. Prior to joining Dyne, Dr. Dugar served as vice president and global head of medical affairs at Sarepta Therapeutics, Inc., where he built the company’s medical affairs organization. Previously, he led all commercial and market access efforts for Intra-Cellular Therapies, Inc. as vice president and head of commercial development. Dr. Dugar joined Intra-Cellular Therapies following his tenure at Roche, where he was global head of clinical development science and innovation and global head of the external development group, including work in oligonucleotides. Previously, he spent 13 years at Pfizer Inc. in various roles, most recently serving as vice president, global head of clinical development and medical affairs of the biosimilars business unit. Dr. Dugar began his career at the National Institutes of Health. He completed a pharmacoeconomics and outcomes research fellowship at the University of Michigan School of Public Health. Dr. Dugar earned an MBA from The Pennsylvania State University and a Ph.D. in pharmacology from The Pennsylvania State University College of Medicine.